Avalanche Biotechnologies raises $55 million in series B financing

Avalanche Biotechnologies has completed a $55 million series B financing to advance the company’s clinical programs in retinal disorders, according to a press release. This includes Avalanche’s lead product, AVA-101, a treatment for wet age-related macular degeneration. The company, which focuses on gene therapies for serious eye diseases, will invest in manufacturing and clinical infrastructure for its lead program and accelerate the development of pipeline programs based on the BioFactory platform, the release said.

Full Story →